Research ArticleArticle
Open Access
Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study
Rianne E. van Bentum, Sjoerd C. Heslinga, Michael T. Nurmohamed, Andreas H. Gerards, Ed N. Griep, Charlotte B.J.M. Koehorst, Marc R. Kok, Anna M. Schilder, Marijn Verhoef and Irene E. van der Horst-Bruinsma
The Journal of Rheumatology November 2018, jrheum.180312; DOI: https://doi.org/10.3899/jrheum.180312
Rianne E. van Bentum
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Sjoerd C. Heslinga
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Michael T. Nurmohamed
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Andreas H. Gerards
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Ed N. Griep
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Charlotte B.J.M. Koehorst
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Marc R. Kok
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Anna M. Schilder
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Marijn Verhoef
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Irene E. van der Horst-Bruinsma
From the Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center, Amsterdam; Department of Rheumatology, Franciscus Vlietland Hospital, Schiedam; Department of Rheumatology, Antonius Hospital, Sneek; Department of Rheumatology, Gelre Hospital, Apeldoorn; Department of Rheumatology, Maasstad Hospital, Rotterdam; Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden; Department of Immunology, Merck Sharp & Dohme (MSD), Haarlem, the Netherlands. This is an investigator-initiated study financed by an unrestricted grant from MSD, the Netherlands. R.E. van Bentum, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; S.C. Heslinga, MD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; M.T. Nurmohamed, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, locations Reade and VU University Medical Center; A.H. Gerards, MD, Department of Rheumatology, Franciscus Vlietland Hospital; E.N. Griep, MD, PhD, Department of Rheumatology, Antonius Hospital; C.B. Koehorst, MD, Department of Rheumatology, Gelre Hospital; M.R. Kok, MD, PhD, Department of Rheumatology, Maasstad Hospital; A.M. Schilder, MD, Department of Rheumatology, Medical Centre Leeuwarden; M. Verhoef, MSc, Department of Immunology, MSD, the Netherlands; I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, Amsterdam Rheumatology and immunology Center, locations Reade and VU University Medical Center. Dr. van Bentum and Dr. Heslinga contributed equally to this work. Address correspondence to Dr. I.E. van der Horst-Bruinsma, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Room 3A47, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: ie.vanderhorst@vumc.nl. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 16, 2018.
Abstract
Objective Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS). Golimumab (GOL), a tumor necrosis factor-α inhibitor (TNFi), has proven to be effective in the treatment of AS. To date, the effect of GOL on the incidence of AAU in AS is unknown. The objective was to study the AAU occurrence rate in patients with AS during GOL treatment and secondarily, the efficacy of GOL in daily clinical practice.
Methods The study was a multicenter prospective study in a real-world setting in patients with AS who were treated with GOL for 12 months. The occurrence of AAU was assessed in the year before the initial TNFi treatment and during GOL treatment and calculated for the period at risk for a new AAU. Measures for disease activity [Ankylosing Spondylitis Disease Activity Score (ASDAS)] and treatment response [Assessment of Spondyloarthritis international Society (ASAS20 score)] were collected.
Results In total, 93 patients (65% male, 55% TNFi-naive, 27% history of AAU) were included, with a median disease duration of 7 years and ASDAS score of 3.1. During GOL treatment, the AAU occurrence rate was reduced from 11.1 to 2.2 per 100 patient-years (rate-ratio 0.20, 95% CI 0.04–0.91). After 3 months of treatment, 41% of the patients experienced a clinically important improvement of the ASDAS score (p < 0.001) and 36% an ASDAS20 response (p < 0.001). At month 12, 49% had achieved an ASAS20 response (p < 0.001).
Conclusion In AS, the AAU occurrence rate and disease activity decreased significantly during GOL treatment. Therefore, GOL can be considered a good choice in patients with AS who need a TNFi, especially in cases of recurrent AAU. (EudraCT number: 2012-002458-21)
In this issue
The Journal of Rheumatology
Vol. 46, Issue 5
1 May 2019
Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study
Rianne E. van Bentum, Sjoerd C. Heslinga, Michael T. Nurmohamed, Andreas H. Gerards, Ed N. Griep, Charlotte B.J.M. Koehorst, Marc R. Kok, Anna M. Schilder, Marijn Verhoef, Irene E. van der Horst-Bruinsma
The Journal of Rheumatology Nov 2018, jrheum.180312; DOI: 10.3899/jrheum.180312
Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study
Rianne E. van Bentum, Sjoerd C. Heslinga, Michael T. Nurmohamed, Andreas H. Gerards, Ed N. Griep, Charlotte B.J.M. Koehorst, Marc R. Kok, Anna M. Schilder, Marijn Verhoef, Irene E. van der Horst-Bruinsma
The Journal of Rheumatology Nov 2018, jrheum.180312; DOI: 10.3899/jrheum.180312
